Objective[|]In dynamic renal scans, 99mTc-diethylenetriamine pentaacetic acid (DTPA) is copiously used and it yields information about the renal blood-flow and the excretory capacity. 99mTc-dimercaptosuccinic acid (DMSA) is used for static renal imaging and can likewise uncover the renal cortical structure. This work was intended to evaluate whether DMSA can be declared as a radiopharmaceutical in dynamic renal scans or not. It also aimed at comparing the outcomes procured from DMSA and with DTPA examinations.[¤]Materials and Methods[|]A comparison of the information gained from the renograms of 47 subjects (normal subjects and subjects with abnormal renal function having: obstructive nephropathy, bilateral nephropathy, hydronephrosis, reduced or non-function kidney, and/or atrophic kidney) who had 99mTc-DMSA and 99mTc-DTPA dynamic scintigraphies utilizing the same protocol.[¤]Results[|]A strong positive correlation had come in view on the evaluation of the left kidney, right kidney, and total glomerular filtration rate (GFR) from 99mTc-DTPA and 99mTc-DMSA renograms. In addition, the estimation of the time of the peak height from 99mTc-DTPA and 99mTc-DMSA renograms for the right and left kidneys demonstrated as non-significant varieties and a strong positive correlation for both the normal subjects and subjects with kidney abnormalities.[¤]Conclusion[|]In the light of the outcomes gained from the present investigation, it could be prescribed that 99mTc-DMSA can favorably replace 99mTc-DTPA in dynamic renograms in the case of the renal conditions that had been examined in the present work. As scheduled, this will be cost-effective and time saving and will decrease the radiation dose administered to the subjects. Also, the same qualities of results are accomplished with both radiopharmaceuticals in normal subjects and subjects with abnormal renal function.[¤]